Jubilant Life Sciences’ arm Jubilant Biosys gets milestone payment from AstraZeneca

Jubilant Life Sciences’ unit Jubilant Biosys has received an undisclosed amount as a milestone payment from AstraZeneca for its research on pain management in the neuroscience therapeutic area.

The alliance between Jubilant and London-headquartered drug firm AstraZeneca in the neuroscience therapeutic area began two years ago. Two years collaboration in neuroscience therapeutic area has now expanded to cardiovascular and metabolic diseases and focuses on the delivery of a steady stream of pre-clinical outcomes to AstraZeneca by Jubilant.

AstraZeneca owns the compounds developed under the collaboration with worldwide development and commercialization rights. On the other hand, Jubilant derives research funding and success-based development and commercialization milestone payments.